NCT07120425View on ClinicalTrials.gov

A Study of IBI3032 in Healthy Participants

PHASE1RecruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

September 10, 2025

Primary Completion Date

November 13, 2025

Study Completion Date

November 13, 2025

Conditions
Healthy
Interventions
DRUG

IBI3032

"IBI3032:~Method of administration: oral, fasted administration."

DRUG

placebo

Placebo (without active ingredients) Method of administration: oral, fasted administration.

Trial Locations (1)

66219

RECRUITING

ICON Clinical Research, Lenexa

All Listed Sponsors
lead

Fortvita Biologics (USA)Inc.

INDUSTRY

NCT07120425 - A Study of IBI3032 in Healthy Participants | Biotech Hunter | Biotech Hunter